Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Leukemia
; 35(7): 1864-1872, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1216445
ABSTRACT
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Leukemia, Hairy Cell
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Leukemia
Journal subject:
Hematology
/
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
S41375-021-01257-7
Similar
MEDLINE
...
LILACS
LIS